Skip to content
value.today

Syntis Bio, Inc.

🇺🇸 Milton, Massachusetts, USABiotechnologyFounded 2022
Total raised
$47 M
3 rounds on record
Latest round
$25 M
Jun 2025
First round on record
Aug 2022
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Syntis Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$25 MNo. 3$10 to $50 million

Syntis Bio, Inc.: Raise no. 3, Jun 2025

Investors in this round

12 investors had bought by the notice of Jul 2, 2025: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $26 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rahul Dhanda · Executive Officer, Director
  • Carlo Giovanni Traverso · Director
  • Chenny Zhang · Director
  • Martin Madaus · Director
  • Michael Nannizzi · Director
  • Robert Langer · Director
  • Teymour Boutros-Ghali · Director
  • Teymour Boutros-Ghali · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rahul Dhanda, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 2, 2025. Read the notice at the SEC.

equitySEC
Dec 2024$6 MNo. 2$2 to $10 million

Syntis Bio, Inc.: Raise no. 2, Dec 2024

Investors in this round

9 investors had bought by the notice of Jan 27, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $9 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Simple agreement for future equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rahul Dhanda · Executive Officer, Director
  • Carlo Giovanni Traverso · Director
  • Martin Madaus · Director
  • Robert Langer · Director
  • Teymour Boutros-Ghali · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rahul Dhanda, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 27, 2025. Read the notice at the SEC.

equity, optionsSEC
Aug 2022$15 MNo. 1$10 to $50 million

Syntis Bio, Inc.: Raise no. 1, Aug 2022

Investors in this round

15 investors had bought by the notice of Jan 17, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rahul K. Dhanda · Executive Officer, Director
  • Carlo Giovanni Traverso · Director
  • Martin Giovanni Madaus · Director
  • Robert Giovanni Langer · Director
  • Teymour Giovanni Boutros-Ghali · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rahul K. Dhanda, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 17, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Syntis Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2025

That is all the official record says: Syntis Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Syntis Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Syntis Bio, Inc.
NameRoleNamed in
Rahul DhandaExecutive officerJul 2025
Rahul K. DhandaExecutive officerJan 2023
Carlo Giovanni TraversoDirectorJul 2025
Chenny ZhangDirectorJul 2025
Martin MadausDirectorJul 2025
Michael NannizziDirectorJul 2025
Rahul DhandaDirectorJul 2025
Robert LangerDirectorJul 2025
Teymour Boutros-GhaliDirectorJul 2025
Martin Giovanni MadausDirectorJan 2023
Rahul K. DhandaDirectorJan 2023
Robert Giovanni LangerDirectorJan 2023
Teymour Giovanni Boutros-GhaliDirectorJan 2023